Generate a tailored SOP for Dr. Antoni Ribas. Improve your application with a focused, well-structured draft.
Antoni Ribas, M.D., Ph.D., is a physician-scientist who conducts laboratory and clinical research focused on malignant melanoma. His research concentrates on gene engineered T-cells, PD-1 blockade therapy, and BRAF targeted therapies. Dr. Ribas is affiliated with the National Cancer Institute (NCI) and heads a laboratory in California that develops models to test new therapeutic options and study the mechanisms of action of treatments and the molecular mechanisms of therapy resistance. He has been instrumental in the clinical development of several agents that have been approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar), and trametinib (Mekinist).
Department of Economics admits primarily for the PhD program.